Revolution Medicines (RVMD) Other Non-Current Assets (2019 - 2026)

Revolution Medicines' Other Non-Current Assets history runs 8 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 10.26% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $14.5 million, a 10.26% increase from a year earlier, with the FY2025 full-year figure at $14.8 million, up 748.39% from the prior year.
• Other Non-Current Assets eased to $14.5 million in Q1 2026 per RVMD's latest filing, from $14.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $14.9 million in Q3 2025 and bottomed at $725000.0 in Q2 2022.
• The 5-year median for Other Non-Current Assets is $3.0 million (2024), against an average of $6.0 million.
• Across the five-year window, Other Non-Current Assets soared 1226.17% in 2023 and sank 75.23% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $2.9 million in 2022, then jumped by 146.13% to $7.0 million in 2023, then sank by 75.23% to $1.7 million in 2024, then soared by 748.39% to $14.8 million in 2025, then declined by 2.03% to $14.5 million in 2026.
• Per Business Quant, the three latest RVMD Other Non-Current Assets figures stand at $14.5 million (Q1 2026), $14.8 million (Q4 2025), and $14.9 million (Q3 2025).